Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma Overexpressing KIT
NCT00180921Phase 2Unknown
- Sponsor
- Gustave Roussy
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in adenoid cystic carcinoma (ACC), sponsored by Gustave Roussy. Primary endpoint: Progression-Free Survival at 6 months. Status: unknown.
02
Drugs
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT00180921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00180921.